Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 26(6):809–815

PubMed  PubMed Central  Google Scholar 

Li CI, Anderson BO, Daling JR, Moe RE (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289(11):1421–1424

PubMed  Google Scholar 

Dossus L, Benusiglio PR (2015) Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 17:37

PubMed  PubMed Central  Google Scholar 

García-Fernández A, Lain JM, Chabrera C, García Font M, Fraile M, Barco I, Torras M, Reñe A, González S, González C, Piqueras M (2015) Comparative long-term study of a large series of patients with invasive ductal carcinoma and invasive lobular carcinoma. Loco-regional recurrence, metastasis, and survival. Breast J 21(5):533–7

PubMed  Google Scholar 

Adachi Y, Ishiguro J, Kotani H, Hisada T, Ichikawa M, Gondo N, Yoshimura A, Kondo N, Hattori M, Sawaki M et al (2016) Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer 16:248

PubMed  PubMed Central  Google Scholar 

Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM (2022) Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat 193(2):253–264

PubMed  Google Scholar 

Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA et al (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20(2):379–387

CAS  PubMed  Google Scholar 

Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, Dankerl A, Glatting G, Reske S, Mattfeldt T (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29(10):1317–1323

CAS  PubMed  Google Scholar 

Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA (2015) Comparison of 18F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nucl Med 56(11):1674–1680

CAS  PubMed  Google Scholar 

National comprehensive cancer network guidelines version i.2024.invasive breast cancer. http://www.nccn.org. Accessed 11 Nov 2024

Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F et al (2014) A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 50(2):277–289

CAS  PubMed  Google Scholar 

Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A et al (2012) Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30(6):587–592

PubMed  Google Scholar 

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892

CAS  PubMed  PubMed Central  Google Scholar 

McGranahan N, Swanton C (2017) Clonal Heterogeneity and tumor evolution: past, present, and the Future. Cell 168(4):613–628

CAS  PubMed  Google Scholar 

Giuliano M, Schifp R, Osborne CK, Trivedi MV (2011) Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 20(Suppl 3):S42-49

PubMed  Google Scholar 

Sighoko D, Liu J, Hou N, Gustafson P, Huo D (2014) Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification? Oncologist 19(6):592–601

PubMed  PubMed Central  Google Scholar 

Ulaner GA, Vaz SC (2024) Women’s health update: growing role of pet for patients with breast cancer. Semin Nucl Med 54(2):247–255

PubMed  Google Scholar 

Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden HM (2020) Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16α-18f-fluoro-17β-estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications. Oncologist 25(10):835–844

CAS  PubMed  PubMed Central  Google Scholar 

Peterson LM, Kurland BF, Yan F, Jiresova AN, Gadi VK, Specht JM, Gralow JR, Schubert EK, Link JM, Krohn KA et al (2021) F-fluoroestradiol PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer. J Nucl Med 62(2):184–190

CAS  PubMed  PubMed Central  Google Scholar 

Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van’t Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY et al (2018) Intratumor heterogeneity of the estrogen receptor and the long-term risk of fatal breast cancer. J Natl Cancer Inst 110(7):726–733

PubMed  PubMed Central  Google Scholar 

Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K (2014) Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 74(5):1338–1348

CAS  PubMed  PubMed Central  Google Scholar 

Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ (2001) Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19(11):2797–2803

CAS  PubMed  Google Scholar 

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK et al (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24(18):2793–2799

CAS  PubMed  Google Scholar 

Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, Welch MJ, Siegel BA (2009) PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 113(3):509–517

CAS  PubMed  Google Scholar 

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA et al (2014) A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol 16(3):431–440

CAS  PubMed  Google Scholar 

Boers J, Venema CM, de Vries EFJ, Glaudemans AWJM, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP (2020) Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Eur J Cancer 126:11–20

CAS  PubMed  Google Scholar 

Venema C, de Vries E, Glaudemans A, Poppema B, Hospers G, Schröder C (2017) 18F-FES PET has added value in staging and therapy decision making in patients with disseminated lobular breast cancer. Clin Nucl Med 42(8):612–614

PubMed  Google Scholar 

Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A (2021) Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer. J Nucl Med 62(3):326–331

CAS  PubMed  PubMed Central  Google Scholar 

Liu C, Ma G, Xu X, Song S, Yang Z (2024) Can 18F-FES PET Improve the Evaluation of 18F-FDG PET in patients with metastatic invasive lobular carcinoma? Clin Nucl Med 49(4):301–307

PubMed  Google Scholar 

Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C et al (2023) Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in patients with invasive lobular carcinomas. AJR Am J Roentgenol 221(2):228–239

PubMed  Google Scholar 

Byrd DW, Doot RK, Allberg KC, MacDonald LR, McDougald WA, Elston BF, Linden HM, Kinahan PE (2016) Evaluation of cross-calibrated (68)Ge/(68)Ga phantoms for assessing PET/CT measurement bias in oncology imaging for single- and multicenter trials. Tomography 2(4):353–360

PubMed  PubMed Central  Google Scholar 

Kurland BF, Peterson LM, Shields AT, Lee JH, Byrd DW, Novakova-Jiresova A, Muzi M, Specht JM, Mankoff DA, Linden HM et al (2019) Test-retest reproducibility of (18)F-FDG PET/CT uptake in cancer patients within a qualified and calibrated local network. J Nucl Med 60(5):608–614

CAS  PubMed  PubMed Central  Google Scholar 

Tewson TJ, Mankoff DA, Peterson LM, Woo I, Petra P (1999) Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 26(8):905–913

CAS  PubMed  Google Scholar 

Ulaner GA, Mankoff DA, Clark AS, Fowler AM, Linden HM, Peterson LM, Dehdashti F, Kurland BF, Mortimer J, Mouabbi J et al (2023) Summary: appropriate use criteria for estrogen receptor-targeted PET imaging with 16alpha-(18)f-fluoro-17beta-fluoroestradiol. J Nucl Med 64(3):351–354

CAS  PubMed  Google Scholar 

Peterson LM, Kurland BF, Link JM, Schubert EK, Stekhova S, Linden HM, Mankoff DA (2011) Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol 38(7):969–978

CAS  PubMed  PubMed Central  Google Scholar 

Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff D